Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of the feasibility of using circulating tumor cells and peripheral blood cells as biomarkers for predicting the efficacy of concurrent chemoradiotherapy and durvalumab consolidation therapy in patients with locally advanced Non-small cell lung cancer

Next Previous
Trial Profile

Assessment of the feasibility of using circulating tumor cells and peripheral blood cells as biomarkers for predicting the efficacy of concurrent chemoradiotherapy and durvalumab consolidation therapy in patients with locally advanced Non-small cell lung cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics (Primary) ; Durvalumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 18 May 2022 New trial record
  • 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top